Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Most data comes from animal studies, so long-term safety and rare side effects remain unclear
Tumour growth beyond a small volume requires neovascularisation, which is precisely why angiogenesis inhibitors constitute an established class of cancer therapeutics
PubMed De Naeyer A, Pocock V, Milligan S, De Keukeleire D
FDA under the brand Zepbound in November 2023, and by European regulators as Mounjaro in June 2024
US$ 24.19
US$ 22.52
US$ 26.01
US$ 20.49
US$ 20.76
US$ 28.43
US$ 22.72
